Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
View / Open Files
Authors
Corazzelli, Gaetano
Frigeri, Ferdinando
Arcamone, Manuela
Capobianco, Gaetana
Becchimanzi, Cristina
Morelli, Emanuela
Volzone, Francesco
Marcacci, Gianpaolo
Russo, Filippo
De Filippi, Rosaria
Lastoria, Secondo
Pinto, Antonio
Publication Date
2011-12Journal Title
Eur J Haematol
ISSN
0902-4441
Publisher
Wiley
Volume
87
Issue
6
Pages
547-553
Language
eng
Type
Article
This Version
VoR
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Corazzelli, G., Frigeri, F., Arcamone, M., Aloj, L., Capobianco, G., Becchimanzi, C., Morelli, E., et al. (2011). Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.. Eur J Haematol, 87 (6), 547-553. https://doi.org/10.1111/j.1600-0609.2011.01683.x
Abstract
Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120 mg/m(2) every 21 d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+ d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
Keywords
Humans, Lymphoma, T-Cell, Nitrosourea Compounds, Organophosphorus Compounds, Antineoplastic Agents, Alkylating, Aged, Middle Aged
Identifiers
External DOI: https://doi.org/10.1111/j.1600-0609.2011.01683.x
This record's URL: https://www.repository.cam.ac.uk/handle/1810/287417
Rights
Publisher's own licence
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.